---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026385"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:50:15.655512+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Contineum Q2 cash $218.7M; PIPE-307 Phase 2 enrollment on track

## Summary
- Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at year-end 2023.
- R&D expenses $7.9M vs $9.5M YoY; G&A expenses $3.0M vs $1.6M YoY.
- Completed IPO in April 2024, net proceeds $107.9M.
- Phase 2 VISTA trial of PIPE-307 for RRMS enrollment on track, completion expected in 2025.
- Strengthened board and management with four new appointments, including Troy Ignelzi and Sarah Boyce.

## SEC filing metadata
- accession: 0001437749-24-026385
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774924026385/0001437749-24-026385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774924026385/cont20240719c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026385
- JSON: https://secwatch.observer/filing/0001437749-24-026385.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.